As a Potential Treatment Agent for Type 2 Diabetes Mellitus and the Underlying Mechanisms: A Review

Overview

Journal Front Pharmacol

Date 2019 Aug 10

PMID 31396083

Citations 14

Authors

Qian Ran

Jin Wang

Lin Wang

Hai-Rong Zeng

Xiang-Bo Yang

Qin-Wan Huang

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus, especially type 2 diabetes mellitus (T2DM), has become a significant public health burden. (RC), known as , is widely used for treating diabetes in China. The bioactive compounds of RC, especially alkaloids, have the potential to suppress T2DM-induced lesions, including diabetic vascular dysfunction, diabetic heart disease, diabetic hyperlipidemia, diabetic nephropathy, diabetic encephalopathy, diabetic osteopathy, diabetic enteropathy, and diabetic retinopathy. This review summarizes the effects of RC and its bioactive compounds on T2DM and T2DM complications. Less research has been conducted on non-alkaloid fractions of RC, which may exert synergistic action with alkaloids. Moreover, we summarized the pharmacokinetic properties and structure-activity relationships of RC on T2DM with reference to extant literature and showed clearly that RC has potential therapeutic effect on T2DM.

Citing Articles

Plantamajoside improves type 2 diabetes mellitus pancreatic β-cell damage by inhibiting endoplasmic reticulum stress through Dnajc1 up-regulation.

Wang D, Wang Y, Zhao H, Lu P, Li M, Li W World J Diabetes. 2025; 16(2):99053.

PMID: 39959264 PMC: 11718491. DOI: 10.4239/wjd.v16.i2.99053.

Huanglian-Renshen-Decoction Maintains Islet β-Cell Identity in T2DM Mice through Regulating GLP-1 and GLP-1R in Both Islet and Intestine.

Wu W, Gao F, Tang Y, Wang H, Dong H, Lu F Chin J Integr Med. 2024; 31(1):39-48.

PMID: 39551849 DOI: 10.1007/s11655-024-3915-1.

Translating molecular insights into clinical success: alkaloid-based therapies for leukemia.

Goleij P, Tabari M, Rezaee A, Sanaye P, Daglia M, Alijanzadeh D Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39476244 DOI: 10.1007/s00210-024-03540-7.

Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Using Virtual Screening, Bioactivity Evaluation, and Binding Studies.

Zhao Z, Ma R, Ma Y, Zhao L, Wang L, Fang Y Molecules. 2024; 29(10).

PMID: 38792165 PMC: 11123979. DOI: 10.3390/molecules29102304.

Mechanism of action of Coptidis Rhizome in treating periodontitis based on network pharmacology and in vitro validation.

Li W, Jiao R, Luo S, Liu Z, Song J, Chen Z BMC Oral Health. 2024; 24(1):530.

PMID: 38704553 PMC: 11069132. DOI: 10.1186/s12903-024-04311-9.

References

Fu D, Wu M, Zhang J, Du M, Yang S, Hammad S . Mechanisms of modified LDL-induced pericyte loss and retinal injury in diabetic retinopathy. Diabetologia. 2012; 55(11):3128-40. PMC: 5922447. DOI: 10.1007/s00125-012-2692-0. View

Chu Z, Jones R, He H, Carroll C, Gutierrez V, Lucman A . A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology. 2007; 148(6):2601-9. DOI: 10.1210/en.2006-1608. View

Goldberg I . Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001; 86(3):965-71. DOI: 10.1210/jcem.86.3.7304. View

Liu X, Li G, Zhu H, Huang L, Liu Y, Ma C . Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. Endocr J. 2010; 57(10):881-93. DOI: 10.1507/endocrj.k10e-043. View

Waldman M, Cohen K, Yadin D, Nudelman V, Gorfil D, Laniado-Schwartzman M . Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'. Cardiovasc Diabetol. 2018; 17(1):111. PMC: 6090985. DOI: 10.1186/s12933-018-0754-4. View

Navedo M, Takeda Y, Nieves-Cintron M, Molkentin J, Santana L . Elevated Ca2+ sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle cells. Am J Physiol Cell Physiol. 2009; 298(2):C211-20. PMC: 2822492. DOI: 10.1152/ajpcell.00267.2009. View

Moerman E, Teng K, Lipschitz D, Lecka-Czernik B . Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. 2004; 3(6):379-89. PMC: 1850101. DOI: 10.1111/j.1474-9728.2004.00127.x. View

Ni W, Ding H, Zhou H, Qiu Y, Tang L . Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats. Eur J Pharmacol. 2015; 764:448-456. DOI: 10.1016/j.ejphar.2015.07.040. View

Kalalian Moghaddam H, Baluchnejadmojarad T, Roghani M, Khaksari M, Norouzi P, Ahooie M . Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats. Mol Neurobiol. 2013; 49(2):820-6. DOI: 10.1007/s12035-013-8559-7. View

10.

Suman R, Borde M, Mohanty I, Maheshwari U, Deshmukh Y . Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction. J Clin Diagn Res. 2016; 10(3):FF13-8. PMC: 4843280. DOI: 10.7860/JCDR/2016/15794.7459. View

11.

Calderon G, Juarez O, Hernandez G, Punzo S, De la Cruz Z . Oxidative stress and diabetic retinopathy: development and treatment. Eye (Lond). 2017; 31(8):1122-1130. PMC: 5558229. DOI: 10.1038/eye.2017.64. View

12.

Zhang W, Xu Y, Guo F, Meng Y, Li M . Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus. Chin Med J (Engl). 2008; 121(21):2124-8. View

13.

Tan X, Ma J, Feng R, Ma C, Chen W, Sun Y . Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One. 2013; 8(10):e77969. PMC: 3815028. DOI: 10.1371/journal.pone.0077969. View

14.

Li H, Wang X, Xu Y, Luo N, Luo S, Hao X . Berberine Improves Diabetic Encephalopathy Through the SIRT1/ER Stress Pathway in db/db Mice. Rejuvenation Res. 2017; 21(3):200-209. DOI: 10.1089/rej.2017.1972. View

15.

Cani P, Bibiloni R, Knauf C, Waget A, Neyrinck A, Delzenne N . Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57(6):1470-81. DOI: 10.2337/db07-1403. View

16.

Li Z, Zhang W . Protective effect of berberine on renal fibrosis caused by diabetic nephropathy. Mol Med Rep. 2017; 16(2):1055-1062. PMC: 5562073. DOI: 10.3892/mmr.2017.6707. View

17.

Turner N, Li J, Gosby A, To S, Cheng Z, Miyoshi H . Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008; 57(5):1414-8. DOI: 10.2337/db07-1552. View

18.

Sankaranarayanan C, Nishanthi R, Pugalendi P . Ameliorating effect of berbamine on hepatic key enzymes of carbohydrate metabolism in high-fat diet and streptozotocin induced type 2 diabetic rats. Biomed Pharmacother. 2018; 103:539-545. DOI: 10.1016/j.biopha.2018.04.066. View

19.

Betteridge D . Diabetic dyslipidaemia. Diabetes Obes Metab. 2001; 2 Suppl 1:S31-6. DOI: 10.1046/j.1463-1326.2000.00021.x. View

20.

Bulani Y, Srinivasan K, Sharma S . Attenuation of type-1 diabetes-induced cardiovascular dysfunctions by direct thrombin inhibitor in rats: a mechanistic study. Mol Cell Biochem. 2018; 451(1-2):69-78. DOI: 10.1007/s11010-018-3394-9. View